Profile of delamanid for the treatment of multidrug-resistant tuberculosis.

Article Details

Citation

Szumowski JD, Lynch JB

Profile of delamanid for the treatment of multidrug-resistant tuberculosis.

Drug Des Devel Ther. 2015 Jan 29;9:677-82. doi: 10.2147/DDDT.S60923. eCollection 2015.

PubMed ID
25678771 [ View in PubMed
]
Abstract

New approaches to the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) are badly needed. Not only is the success rate of current treatment regimens suboptimal but existing regimens require multiple drugs and lengthy courses and may lead to significant toxicities. The treatment landscape is beginning to shift, however, with the recent approvals of the new TB drugs bedaquiline and delamanid. Delamanid, a dihydro-imidazooxazole, has been shown to have excellent activity against Mycobacterium tuberculosis in both in vitro and in murine TB models. It has also recently been reported to improve rates of sputum culture conversion in patients with multidrug-resistant TB when added to an optimized background regimen. Although generally well tolerated, delamanid has been associated with QT prolongation, which may be of particular clinical concern when paired with other TB drugs that may also have this effect, most notably the fluoroquinolones. Ongoing studies will help to clarify delamanid's role in the treatment of drug-resistant TB.

DrugBank Data that Cites this Article

Drugs
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
DelamanidDeazaflavin-dependent nitroreductaseProteinMycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
No
Substrate
Details
Drug Interactions
DrugsInteraction
Delamanid
Midostaurin
The metabolism of Delamanid can be decreased when combined with Midostaurin.
Delamanid
Delavirdine
The metabolism of Delamanid can be decreased when combined with Delavirdine.
Delamanid
Nefazodone
The metabolism of Delamanid can be decreased when combined with Nefazodone.
Delamanid
Ditiocarb
The metabolism of Delamanid can be decreased when combined with Ditiocarb.
Delamanid
Telaprevir
The metabolism of Delamanid can be decreased when combined with Telaprevir.